Nuo Therapeutics (AURX) 10-Q2010 Q2 Quarterly report

Filed: 16 Aug 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accommodate, age, ahead, allocated, allocation, assigned, beneficial, body, borrowing, chain, challenge, charged, classified, compromised, concentration, consolidated, Continence, Council, declined, dedicated, deductible, degradation, delivered, depreciation, discounted, document, effectuating, element, eliminating, Enterostomal, feet, fifteen, flex, free, goodwill, Guarantor, healthcare, hereinafter, highlighting, hired, immaterial, impaired, impairment, impractical, incorrect, inherently, intangible, intrinsic, Joint, lab, lived, medicine, mid, multiple, negligible, occupancy, ordinary, Ostomy, overlapping, owm, paragraph, Patrick, physiologically, pose, preceding, preliminary, President, proceeding, progressing, prove, purport, purpose, quantity, rapid, recalcitrant, rental, representation, reserve, restart, revalued, satisfy, Saul, schedule, serve, shipment, showed, square, straight, suggest, sum, summarized, surgery, tangible, unamortized, underASC, unidentified, unpredictable, usage, Vanek, vest, Vice, view, withASC, World

Removed: active, added, approved, collected, corporation, decreased, Delaware, develop, feedback, Finally, framework, hierarchy, identical, implementation, instrument, likelihood, measuring, observable, quoted, revised, supported, Unobservable, unregistered, utilizing

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

AURX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. §1350

Pursuant to 18 U.S.C. §1350 and in connection with the Quarterly Report on Form 10-Q of Cytomedix, Inc. (the “Company”) for the fiscal period ended June 30, 2010 (the “Report”), I, Andrew S. Maslan, Chief Financial Officer of the Company, hereby certify that to the best of my knowledge and belief:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period.

/s/Andrew S. Maslan
Andrew S. Maslan

Chief Financial Officer

Date: August 16, 2010

A signed original of this written statement has been provided to Cytomedix, Inc. and will be retained by Cytomedix, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.